GlaxoSmithKline (India)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. GlaxoSmithKline (Belgium)比利时4
2. Konyang University韩国1
3. University of North Carolina at Chapel Hill美国1
4. GlaxoSmithKline (United States)美国1
5. The Genetics Society of Korea韩国1
6. University of London英国1
7. GlaxoSmithKline (United Kingdom)英国1
8. Delhi Pharmaceutical Science and Research University印度1

按月发文

逐年被引

最新文献

1. 1
   An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014–2022) Following the Introduction of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and OlderDrug Safety20243
2. 2
   Finding Needles in the Haystack: Clinical Utility Score for Prioritisation (CUSP), an Automated Approach for Identifying Spontaneous Reports with the Highest Clinical UtilityDrug Safety20238
3. 3
   Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup RiskDrug Safety202310
4. 4
   Pharmacovigilance in India: Present Scenario and Future ChallengesDrug Safety201876
5. 5
   Six‐year multi‐centre, observational, post‐marketing surveillance of the safety of the HPV‐16/18 AS04‐adjuvanted vaccine in women aged 10–25 years in KoreaPharmacoepidemiology and Drug Safety20172
6. 6
   Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessmentBMC Public Health201625

高被引文献

1. 1
   Pharmacovigilance in India: Present Scenario and Future ChallengesDrug Safety201876
2. 2
   Parental knowledge, attitudes and perception of pneumococcal disease and pneumococcal conjugate vaccines in Singapore: a questionnaire-based assessmentBMC Public Health201625
3. 3
   Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup RiskDrug Safety202310
4. 4
   Finding Needles in the Haystack: Clinical Utility Score for Prioritisation (CUSP), an Automated Approach for Identifying Spontaneous Reports with the Highest Clinical UtilityDrug Safety20238
5. 5
   An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014–2022) Following the Introduction of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and OlderDrug Safety20243
6. 6
   Six‐year multi‐centre, observational, post‐marketing surveillance of the safety of the HPV‐16/18 AS04‐adjuvanted vaccine in women aged 10–25 years in KoreaPharmacoepidemiology and Drug Safety20172

主要发表期刊